Section 9.00 Endocrine Disorders in 2026: The Blue Book Section With No Listings, the Cross-Reference Map for Diabetes and Thyroid and Adrenal Disease, and the Rule Change Effective August 14, 2026

Section 9.00 of the Blue Book is the strangest section in Appendix 1 to Subpart P of Part 404. It exists. It has a section header. But it contains no medical listings the way Section 1 has 1.15 through 1.24 or the way Section 11 has 11.02 through 11.24. Since 2011 the SSA has treated endocrine disorders as a cross-reference framework rather than a set of listings. This has created decades of confusion for diabetes patients, thyroid patients, adrenal patients, and pituitary patients who filed for disability expecting to meet a specific number and were told their disorder has to be evaluated through the body system it damages. This guide walks through how Section 9.00 actually works in 2026, which Sections take over for each endocrine gland, the exact regulatory text driving the framework, and the announced Section 9.00 rule change effective August 14, 2026 that codifies a decade of practice.

Why Section 9.00 Has No Listings

Before 2011 the Blue Book had specific numbered endocrine listings. Old Listing 9.02 covered thyroid disorders. Old Listing 9.03 covered hyperparathyroidism. Old Listing 9.04 covered hypoparathyroidism. Old Listing 9.06 covered adrenal hyperfunction. Old Listing 9.08 covered diabetes mellitus with three specific paragraphs A, B, and C.

The SSA removed all of these on June 7, 2011. The reason cited in the notice was that most endocrine disorders do not reach listing-level severity because they do not become sufficiently severe or do not remain at a sufficient level of severity long enough to meet the 12-month duration requirement. Modern hormone replacement therapy, insulin regimens, and thyroid medication generally control the endocrine disorder itself. What disables people is not the hormonal imbalance in isolation. It is the damage the imbalance causes to other body systems over time.

The 2011 revision put a note in place of the old listings. Section 9.00A said the SSA evaluates the effects of endocrine disorders under the listings for other body systems. Section 9.00B walked through gland-by-gland examples. Section 9.00C said that when the effects do not meet a listing in another body system, the analyst continues to Steps 4 and 5 of the sequential evaluation. That structure has controlled Section 9 cases from 2011 through 2026.

The 2026 Rule Change

Appendix 1 to Subpart P of Part 404 contains a schedule of when each body system rule set is up for review or has an effective date. The 2026 schedule lists Endocrine Disorders (9.00 and 109.00) with an effective date of August 14, 2026. The scheduled rule update codifies fifteen years of practice under the cross-reference framework. It does not add new endocrine listings. It restates the cross-reference approach with clearer body-system pointers and updates the examples for diabetes complications, thyroid effects, and adrenal effects to reflect current medical practice.

What this means for claimants filing in the second half of 2026 is that the practice does not change. Diabetes is still evaluated through the sections that cover the disabling complication. Thyroid disease is still evaluated through the sections that cover the arrhythmia, weight loss, stroke, cognitive change, or mood change caused by hormone imbalance. But the regulatory text will be cleaner, and DDS analysts will have less room to interpret ambiguous prior language differently across states.

The Exact Text of Section 9.00 in 2026

The 2026 Section 9.00 reads in relevant part:

9.00 Endocrine Disorders.

A. What is an endocrine disorder? An endocrine disorder is a medical condition that causes a hormonal imbalance. When an endocrine gland functions abnormally, producing too much or too little of a hormone, that imbalance can disrupt many bodily processes.

B. How do we evaluate the effects of endocrine disorders? We evaluate impairments that result from endocrine disorders under the listings for other body systems.

Section 9.00B then walks through five gland systems with cross-references to specific body-system listings. Section 9.00C addresses cases where the effects do not meet or medically equal any listing and moves the file to Steps 4 and 5. This is the framework in full. There is no 9.01. There is no 9.02. There are no numbered endocrine listings.

Diabetes Mellitus in Section 9.00

Diabetes is by far the most common endocrine disorder in disability claims. The Centers for Disease Control and Prevention reports that 38.4 million Americans have diagnosed or undiagnosed diabetes as of the most recent National Diabetes Statistics Report. Section 9.00B specifically lists diabetes complications and where they get evaluated.

Diabetic peripheral neuropathy

Evaluated under Section 11.14 for peripheral neuropathy. The listing requires disorganization of motor function in two extremities resulting in an extreme limitation in the ability to stand up from a seated position, balance while standing or walking, or use the upper extremities. Or marked limitation in physical functioning plus one marked area of mental functioning under the paragraph B criteria.

Diabetic retinopathy

Evaluated under Section 2.02 for loss of central visual acuity (remaining vision in the better eye 20/200 or worse after best correction), Section 2.03 for loss of visual efficiency, or Section 2.04 for loss of visual efficiency plus visual field. Proliferative diabetic retinopathy with severe vision loss usually meets one of these.

Diabetic nephropathy

Evaluated under Section 6.03 for chronic kidney disease requiring hemodialysis or peritoneal dialysis, Section 6.04 for chronic kidney disease with kidney transplant (automatic 12-month allowance), or Section 6.05 for chronic kidney disease with laboratory findings and complications.

Diabetic gastroparesis

Evaluated under Section 5.00 digestive disorders. Chronic weight loss below 17.50 BMI for six months on repeated measurements meets Listing 5.08. Recurrent hospitalizations for gastroparesis-related complications can support a Section 5 finding.

Diabetic peripheral neurovascular disease

When diabetic vascular disease progresses to gangrene and amputation, Section 1.20 for amputations applies. Below-knee amputation of one lower extremity or amputation of both hands, or one hand and one lower extremity, meets Listing 1.20 with additional criteria.

Diabetic ketoacidosis and severe hypoglycemia

Section 9.00 tells the analyst that severe hypoglycemia leading to seizures or loss of consciousness is evaluated under Section 11.00 neurological disorders. Altered mental status and cognitive deficits from repeated severe hypoglycemia are evaluated under Section 12.00 mental disorders. Recurrent DKA from mood or eating disorders can be evaluated through both Section 5.00 and Section 12.00.

Diabetes-related coronary artery disease

Evaluated under Section 4.02 for chronic heart failure or Section 4.04 for ischemic heart disease.

Diabetes-related skin infections

Poorly healing bacterial and fungal skin infections in diabetic patients can qualify under Listing 8.04 for hidradenitis suppurativa or Listing 8.09 for chronic skin conditions when the infection pattern meets the functional criteria.

The single most common Step 3 route for diabetic patients is Section 11.14 peripheral neuropathy plus concurrent damage in another system. Analysts are used to seeing combined files. Diabetes with severe neuropathy plus stage 4 CKD plus retinopathy is a strong file even when no single body system meets a listing on its own.

Thyroid Gland Disorders in Section 9.00

Thyroid disease affects an estimated 20 million Americans. Section 9.00B addresses thyroid disorders through four cross-references.

Thyroid-related arrhythmias and heart disease

Evaluated under Section 4.05 for recurrent arrhythmias. Hyperthyroid atrial fibrillation with uncontrolled ventricular response, or thyroid storm with cardiac collapse, may meet this listing when recurrent episodes are documented.

Thyroid-related weight loss

Evaluated under Section 5.08 for chronic weight loss below 17.50 BMI on two measurements at least 60 days apart in a 6-month period.

Thyroid-related strokes

Evaluated under Section 11.04 for vascular insult to the brain. Hypertensive cerebrovascular accidents secondary to poorly controlled thyroid hypertension are a recognized pathway.

Thyroid-related cognitive and mood changes

Evaluated under Section 12.02 for neurocognitive disorders, Section 12.04 for depressive and bipolar disorders, or Section 12.06 for anxiety disorders. Severe hypothyroidism can produce measurable cognitive impairment. Severe hyperthyroidism can produce panic and mood dysregulation. Both are evaluable under Section 12.

Parathyroid Gland Disorders in Section 9.00

Parathyroid disease is less common but produces distinctive effects that map to multiple Sections.

Parathyroid-related osteoporosis and fractures

Evaluated under Section 1.00 musculoskeletal disorders. Fragility fractures of the spine or hip in a hyperparathyroid patient can meet listings such as 1.15 for disorders of the skeletal spine or through the ability to walk framework in 1.17.

Parathyroid-related cataracts

Elevated calcium from hyperparathyroidism can produce cataracts evaluated under Section 2.02 or 2.04 for loss of visual acuity or visual efficiency.

Parathyroid-related kidney failure

Hypercalcemic nephropathy is evaluated under Section 6.00 genitourinary listings. Section 6.03 covers dialysis-requiring CKD.

Parathyroid-related tetany and neuromuscular effects

Hypocalcemia with tetany or muscle spasms is evaluated under Section 11.00 neurological. Severe recurrent tetany can meet neurological criteria when episodes are documented.

Adrenal Gland Disorders in Section 9.00

Adrenal disorders cover Cushing syndrome, Addison disease, primary hyperaldosteronism, pheochromocytoma, and congenital adrenal hyperplasia.

Adrenal-related osteoporosis and fractures

Chronic hypercortisolism from Cushing syndrome or long-term glucocorticoid therapy produces fragility fractures evaluated under Section 1.00. When fractures compromise the ability to walk or use the upper extremities, Section 1.18 or 1.20 may apply.

Adrenal-related hypertension and heart failure

Adrenal hypertension from pheochromocytoma or primary aldosteronism that produces heart failure meets Section 4.02. Adrenal hypertension producing recurrent arrhythmias meets Section 4.05.

Adrenal-related weight loss and cachexia

Addison disease with chronic weight loss and cachexia can meet Section 5.08.

Adrenal-related mood disorders

Cushing syndrome produces depression, mania, and psychosis in a documented proportion of patients. Addison disease produces depression and cognitive slowing. Both fit Section 12.

Pituitary Gland Disorders in Section 9.00

The pituitary is the master gland. Pituitary dysfunction cascades into every other endocrine axis.

Pituitary hypofunction with diabetes insipidus

When ADH deficiency leads to water and electrolyte imbalance and recurrent dehydration, Section 9.00B tells the analyst to evaluate under Section 6.00 genitourinary. Recurrent hypernatremic dehydration episodes fit here.

Pituitary tumors with mass effect

Pituitary macroadenomas causing visual field loss through optic chiasm compression meet Section 2.04 for loss of visual efficiency plus visual field. Tumors producing cognitive change fit Section 12.02.

Growth hormone deficiency

Adult growth hormone deficiency does not typically meet a listing. Childhood growth hormone deficiency may support a case through combined effects on growth, mental development, and cardiovascular function.

Acromegaly

Acromegaly produces cardiac disease, sleep apnea, arthropathy, and diabetes. Each downstream effect is evaluated under its own body system listing. Combined files are common.

Hyperprolactinemia and hypopituitarism

Hormone replacement usually controls the metabolic side. Residual mood, cognitive, or sexual dysfunction may support Section 12 evaluations. Adrenal insufficiency from pituitary hypofunction fits the adrenal pathway above.

When No Listing Is Met

Section 9.00C reads that when an endocrine disorder does not meet or medically equal a listing in another body system, the analyst proceeds to Steps 4 and 5 of the sequential evaluation. Most endocrine cases go this route. The framework at Step 5 is the residual functional capacity assessment described in 20 CFR 404.1545 and 416.945.

The RFC captures the maximum work you can do despite your impairments. Endocrine cases at Step 5 often turn on:

• Fatigue from chronic hypothyroidism, adrenal insufficiency, or advanced diabetes.
• Cognitive slowing documented by neuropsychological testing in poorly controlled diabetes, cortisol excess, or thyroid disease.
• Frequent glycemic emergencies that produce unpredictable absence and safety concerns for driving, working at heights, or operating machinery.
• Chronic pain from diabetic neuropathy that limits standing and walking tolerance below sedentary thresholds.
• Immunosuppression side effects when Cushing syndrome or exogenous steroids are treatment.

Analysts and administrative law judges weigh RFC evidence heavily in endocrine cases. Treating physician RFC forms addressing sitting tolerance, standing tolerance, walking tolerance, lifting, reaching, handling, and expected off-task time and absence per month are the single strongest evidence at Step 5.

Common Filing Errors in Endocrine Cases

Filing under Section 9 alone

The disability report form has a section for the primary impairment. Writing diabetes or hypothyroidism alone in that field without identifying the specific complication that disables you causes the DDS analyst to spend the first weeks of your case searching for a listing that does not exist. The stronger approach is to write diabetic peripheral neuropathy with foot ulcers or hypothyroid myopathy with cognitive impairment. Identify the downstream damage.

Missing the combined-effect argument

Endocrine disorders rarely disable through a single system. Diabetes with mild neuropathy plus stage 3 CKD plus retinopathy plus depression may not meet any single listing but combines to preclude sustained work. The file needs a combined-effect argument documented in every treating source statement and in the personal function report.

Underweighting mental effects

Endocrine disorders produce real cognitive and mood changes. Neuropsychological testing is often the missing evidence in endocrine files. Working memory, processing speed, and sustained attention testing should be part of any complex endocrine claim. Section 12 findings then combine with the physical effects at Step 5.

Not documenting emergency events

Recurrent DKA, recurrent severe hypoglycemia, thyroid storm, adrenal crisis, and pituitary apoplexy are the emergency events that drive many endocrine cases. Each event needs a record. Emergency department notes, hospital admission summaries, and outpatient follow-up documentation together build the frequency and severity picture.

Worked Case Examples

Case One, Marcus, 54, North Carolina

Marcus has type 2 diabetes diagnosed in 2010. By 2024 he had proliferative diabetic retinopathy in both eyes with best-corrected visual acuity of 20/300 in the right eye and 20/400 in the left. He also had stage 4 CKD with eGFR 21 and severe peripheral neuropathy with 10/10 monofilament loss and severe balance deficits. No single listing was met initially. His attorney developed the file: 2.02 vision was borderline, Section 11.14 neuropathy was borderline, and Section 6.05 CKD was documented. At Step 5 the combined RFC limited him to less than sedentary work with need for frequent breaks and off-task time exceeding employer tolerances. Combined-effect analysis approved at the hearing level.

Case Two, Priya, 42, Illinois

Priya has Cushing syndrome secondary to a pituitary microadenoma. She has treatment-resistant hypertension, severe proximal muscle weakness, thoracic vertebral compression fractures at T7 and T10 from steroid-induced osteoporosis, severe depression with two hospitalizations for suicidal ideation, and diabetes. Section 1.15 for spine disorder was borderline. Section 12.04 for depressive disorder met paragraph B criteria with marked limitation in social functioning and marked limitation in concentration. Approved at Step 3 under 12.04 with Section 9 endocrine and Section 1 spine as concurrent impairments.

Case Three, Terrell, 38, Georgia

Terrell has type 1 diabetes with brittle glycemic control. He has had 14 severe hypoglycemic events requiring emergency assistance in the past 24 months, three episodes of DKA requiring hospitalization, and progressive cognitive slowing documented by neuropsychological testing. Section 11.02 for seizures does not fit because his loss of consciousness episodes are hypoglycemic. His attorney developed a combined-effect argument: cognitive deficits under 12.02, glycemic instability described through the frequency of emergency events, and safety concerns preventing any work with driving or heights. Approved at Step 5 with the vocational expert testifying that his required off-task time exceeded 20 percent of the workday.

Case Four, Nina, 61, Oregon

Nina has severe primary hyperparathyroidism with recurrent kidney stones, moderate osteoporosis with two vertebral fractures, and confusion attributed to hypercalcemia. She underwent parathyroidectomy which normalized calcium but did not resolve her cognitive complaints. Neuropsychological testing showed persistent memory and executive function deficits. Section 12.02 for major neurocognitive disorder met paragraph B criteria with marked limitation in understanding, remembering, or applying information plus marked limitation in concentration, persistence, or pace. Approved at Step 3.

Special Case: Compassionate Allowance Endocrine Conditions

Most endocrine disorders are not on the Compassionate Allowances list because they respond to hormone replacement or are chronic rather than terminal. However, several rare endocrine conditions are CAL. Adrenoleukodystrophy in its severe forms, malignant multiple endocrine neoplasia, and certain aggressive endocrine cancers appear on the current CAL list. Check the SSA CAL list for the most current entries when your endocrine diagnosis is rare or malignant.

SSDI Versus SSI for Endocrine Claimants

Endocrine claimants who have worked and paid into Social Security typically file SSDI. Adult-onset diabetes often disables people at ages 45 to 60 when work credits are ample. SSI is the fallback for claimants without sufficient work quarters, and for children with endocrine conditions such as congenital adrenal hyperplasia or type 1 diabetes with severe complications. The 2026 Federal Benefit Rate for SSI is 967 dollars per month for an eligible individual.

State Considerations

Endocrine cases move at different speeds depending on your state DDS. See our state pages for high-volume jurisdictions including California, Texas, Florida, New York, Georgia, and North Carolina. Diabetes prevalence and CKD burden are elevated in the Deep South, and DDS offices there see high volumes of combined endocrine files.

Related Blog Articles and Guides

• Listing 11.14 Peripheral Neuropathy in 2026 for the primary path for diabetic neuropathy claims.
• Listing 6.03 Chronic Kidney Disease for diabetic and hypertensive nephropathy claims.
• Listing 12.02 Neurocognitive Disorders for cognitive changes from endocrine disease.
• Listing 7.18 Repeated Complications of Hematological Disorders for the same combined-effect pattern in hematology.

Frequently Asked Questions